---
title: "\"Performance\" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280047064.md"
description: "BAIYUNSHAN PH announced its 2025 annual performance, with operating revenue of 77.656 billion RMB (same below), an increase of 3.6% year-on-year. The net profit attributable to shareholders is 2.983 billion RMB, a growth of 5.2%, with earnings per share of 1.835 RMB. The final dividend is 0.45 RMB"
datetime: "2026-03-22T08:53:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280047064.md)
  - [en](https://longbridge.com/en/news/280047064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280047064.md)
---

# "Performance" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuan

BAIYUNSHAN PH (00874.HK) announced its 2025 annual results, with operating revenue of RMB 77.656 billion, an increase of 3.6% year-on-year. The net profit attributable to shareholders was RMB 2.983 billion, a growth of 5.2%, with earnings per share of RMB 1.835. A final dividend of 45 cents was declared

### Related Stocks

- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [600332.CN](https://longbridge.com/en/quote/600332.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [00874.HK](https://longbridge.com/en/quote/00874.HK.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516610.CN](https://longbridge.com/en/quote/516610.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Visen Pharmaceuticals files HKEX return disclosing share repurchase at HKD 24.41 each](https://longbridge.com/en/news/287049299.md)